EGFR and medical procedure: In a head-to-head comparison of responders vs. non-responders, patients with advanced adenocarcinoma of the lung on gefitinib, an EGFR tyrosine kinase inhibitor, showed significant decrease in tracer uptake seven days after the start of therapy [19].